Skip to main content

Tweets

🔁 Podcast replay: Before Dr. Charles-Schoeman and Dr. Jain return with a new episode, revisit their 2025 discussion on treatment decisions in uncontrolled RA after TNFi failure. Sponsored by AbbVie Medical Affairs + Health Impact. https://t.co/vbc9RRkpwi https://t.co/q0Q9JnlxjW
Dr. John Cush @RheumNow ( View Tweet )
1 hour 54 minutes ago
Do we need Better Strategies to Prevent Osteoporotic Fractures? In a recent JAMA Viewpoints article, Dr. Susan Ott addresses several controversies in preventing osteoporosis (OP) related fractures. https://t.co/YpmyZGCsjz https://t.co/NUkJVcxBjc
Dr. John Cush @RheumNow ( View Tweet )
3 hours 23 minutes ago
Gout Cavalcade (7.10.2026) Dr. Jack Cush reviews the news, journal articles and regulatory decisions from the past week. July is Gout: More than Flares month. https://t.co/I1zWdx9fzU https://t.co/EYQ3D9Z42t
Dr. John Cush @RheumNow ( View Tweet )
4 hours 53 minutes ago
While not a validated Dx tool for gout, AI retinal scanning of digital fundus photography was tested on 107730 pts & showed high ROC - f NIDDM 0.833, Gout 0.832, OP 0.787, HTN 0.740, hyperlipidemia 0.736 & thyroid Dz 0.699 https://t.co/1yrlR04z4g https://t.co/c04YtVVERY
Dr. John Cush @RheumNow ( View Tweet )
18 hours 54 minutes ago
RHEUMATOLOGIST SURVEY ON GOUT - In what percentage of your new Gout patients, do you do arthrocentesis and crystal ID? Answer here: https://t.co/jpebQev4VU

Dr. John Cush @RheumNow ( View Tweet )

19 hours 36 minutes ago
RZV (Shingrix) response in 76 immunosuppressed SSc & 304 controls (CG) recv two RZV doses. High seroconversion seen in SSc but signif lower than CG (92.6% vs 99.7%, P 0.001), w/ lower concentration but comparable CMI, lower AE (74% vs 86%) https://t.co/ALlnVEZIAt https://t.co/kYYy2JIo2J
Dr. John Cush @RheumNow ( View Tweet )
20 hours 24 minutes ago
20 yr. Tx trends in 6583 #SSc pts. 2005 to 2025 endothelin receptor antagonists & prostanoids/prostacyclins from 3% to 28%. CCB & PDE-5 inh stable. CTX shifted to mycophenolate, RTX, & nintedanib. Steriods decr from 50% to 18% https://t.co/nrm1Ov285f https://t.co/ftLn3bGH72
Dr. John Cush @RheumNow ( View Tweet )
23 hours 53 minutes ago
Registration is now open! Join Dr. Jack Cush as he moderates an expert discussion with Dr. Nicola Dalbeth, Dr. John Fitzgerald, and Dr. Sarah Tedeschi on the evolving role of imaging in gout. Topics include: 🔹 Ultrasound 🔹 Dual-energy CT (DECT) 🔹 Crystal identification 🔹 https://t.co/iOOAAAEneX
Dr. John Cush @RheumNow ( View Tweet )
1 day ago
True or False: Extreme weight loss methods such as bariatric surgery and ketogenic diets may trigger gouty attacks, unlike GLP-1 agonist-induced weight loss. Test your RheumIQ in this week's quiz at https://t.co/8BuwihOvfE.

Dr. John Cush @RheumNow ( View Tweet )

1 day ago
EMD Serono Announces FDA Breakthrough Therapy Designation for Enpatoran (TLR 7/8 inhibitors) for use in Cutaneous Lupus; based on the results from the Phase 2 WILLOW study https://t.co/TNM4whC0Qk https://t.co/70Cibg1gkW
Dr. John Cush @RheumNow ( View Tweet )
1 day ago
FDA - a 120Year History Protecting Americans. Nice overview. - Began 1906 (as Bureau of Chemistry) w/ Pure Food & Drugs Act - 1930 changed to Food and Drug Administration - 1938 Food, Drug, and Cosmetics Act - 1960s denied thalidomide approval https://t.co/3Ey98M9sxw My https://t.co/JS36EfJ19k
Dr. John Cush @RheumNow ( View Tweet )
1 day ago
DMARD Efficacy in RA-ILD A network meta-analysis in the Journal of Autoimmunity reviews the pharmacologic options for rheumatoid arthritis–associated interstitial lung disease (RA-ILD). RA-ILD guidelines were recently presented by ERS/EULAR, but these were mainly conditional,

Dr. John Cush @RheumNow ( View Tweet )

1 day ago
×